Prevail Therapeutics Inc.

Industry

  • Biotechnology
    • Large Molecule
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
      • Macromolecule
See more in Biomedtracker

Latest on Prevail Therapeutics Inc.

Pink Sheet

Sangamo’s Fabry Gene Therapy Can Rely On 25-Person Registration Trial After US FDA Meeting

 
• By Kevin Grogan

Sangamo Therapeutics, Inc. believes it has a plan for getting Fabry disease gene therapy isaralgagene civaparvovec to market after positive talks with regulators on both sides of the Atlantic. The ge

Scrip

Sangamo Shoots Up As Regulatory Path Clears For Fabry Gene Therapy

 
• By Kevin Grogan

Shares in Sangamo Therapeutics, Inc. have jumped by 40% on promising data for isaralgagene civaparvovec for Fabry disease and positive talks with regulators on both sides of the Atlantic about getti

Scrip

Allo CAR-T Is Still On The Shelf As Precision Moves On

 
• By Andrew McConaghie

Precision BioSciences , which had hoped to be the first company to bring an allogeneic CAR-T to market, has announced its exit from the field with the sale of its lead asset, azercabtagene zapreleucel

Scrip

Deal Watch: Sangamo Inks Significant Option Deal With Prevail After Losing Tie-Ups With Novartis, Biogen

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sangamo Partners In Neurology With Lill